| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
|
Loibl, S.
|
|
|
30 |
8 |
p. 1279-1288
|
artikel
|
| 2 |
Cancer mortality in Europe in 2015 and an overview of trends since 1990
|
Bertuccio, P.
|
|
|
30 |
8 |
p. 1356-1369
|
artikel
|
| 3 |
Cancer mortality in the elderly in 11 countries worldwide, 1970–2015
|
Carioli, G.
|
|
|
30 |
8 |
p. 1344-1355
|
artikel
|
| 4 |
Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
|
Chugh, R.
|
|
|
30 |
8 |
p. 1405
|
artikel
|
| 5 |
Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
|
Swain, S.M.
|
|
|
30 |
8 |
p. 1404
|
artikel
|
| 6 |
Correction to: Surgery in reference centers improves survival of sarcoma patients: a nationwide study
|
Blay, J.-Y.
|
|
|
30 |
8 |
p. 1407
|
artikel
|
| 7 |
Corrigendum to: Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors
|
Diossy, M.
|
|
|
30 |
8 |
p. 1406
|
artikel
|
| 8 |
Current status of immune checkpoint inhibition in early-stage NSCLC
|
Vansteenkiste, J.
|
|
|
30 |
8 |
p. 1244-1253
|
artikel
|
| 9 |
Does adjuvant therapy reduce postmetastatic survival?
|
Fink, M.K.
|
|
|
30 |
8 |
p. 1184-1188
|
artikel
|
| 10 |
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
|
Cardoso, F.
|
|
|
30 |
8 |
p. 1194-1220
|
artikel
|
| 11 |
Editorial board
|
|
|
|
30 |
8 |
p. ii-iii
|
artikel
|
| 12 |
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer
|
Früh, M.
|
|
|
30 |
8 |
p. 1190-1192
|
artikel
|
| 13 |
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
|
Hastings, K.
|
|
|
30 |
8 |
p. 1311-1320
|
artikel
|
| 14 |
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
|
Luchini, C.
|
|
|
30 |
8 |
p. 1232-1243
|
artikel
|
| 15 |
Extending the interval to surgery in rectal cancer and filling the time with chemotherapy—how much is enough?
|
Glynne-Jones, R.
|
|
|
30 |
8 |
p. 1188-1190
|
artikel
|
| 16 |
Extramural spread of rectal cancer and the AJCC Cancer Staging Manual 8th edition, 2017
|
Nicholls, R.J.
|
|
|
30 |
8 |
p. 1394-1395
|
artikel
|
| 17 |
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
|
Oliveira, M.
|
|
|
30 |
8 |
p. 1289-1297
|
artikel
|
| 18 |
Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group
|
Mandelker, D.
|
|
|
30 |
8 |
p. 1221-1231
|
artikel
|
| 19 |
Hodgkin lymphoma, treatment and thrombosis: a dangerous mix
|
Connors, J.M.
|
|
|
30 |
8 |
p. 1192-1193
|
artikel
|
| 20 |
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|
Mazieres, J.
|
|
|
30 |
8 |
p. 1321-1328
|
artikel
|
| 21 |
Letters to the editor
|
Marsden, J.
|
|
|
30 |
8 |
p. 1393-1394
|
artikel
|
| 22 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study
|
Ciseł, B.
|
|
|
30 |
8 |
p. 1298-1303
|
artikel
|
| 23 |
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
|
Henon, C.
|
|
|
30 |
8 |
p. 1401-1403
|
artikel
|
| 24 |
Maintenance lenalidomide in primary CNS lymphoma
|
Rubenstein, J.L.
|
|
|
30 |
8 |
p. 1397-1398
|
artikel
|
| 25 |
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
|
Khoja, L.
|
|
|
30 |
8 |
p. 1370-1380
|
artikel
|
| 26 |
Molecular pathology of tumors of the central nervous system
|
Kristensen, B.W.
|
|
|
30 |
8 |
p. 1265-1278
|
artikel
|
| 27 |
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages
|
Gomez-Roca, C.A.
|
|
|
30 |
8 |
p. 1381-1392
|
artikel
|
| 28 |
Pre-treated anti-PD-1 refractory Merkel cell carcinoma successfully treated with the combination of PD-1/PD-L1 axis inhibitors and TVEC: a report of two cases
|
Knackstedt, R.
|
|
|
30 |
8 |
p. 1399-1400
|
artikel
|
| 29 |
Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer
|
Pentheroudakis, G.
|
|
|
30 |
8 |
p. 1395-1397
|
artikel
|
| 30 |
Reply to the letter to the editor ‘European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al’ by Marsden and Hamoda, On behalf of the British Menopause Society Medical Advisory Council
|
Malvezzi, M.
|
|
|
30 |
8 |
p. 1394
|
artikel
|
| 31 |
Reply to the letter to the editor ‘Maintenance lenalidomide in primary CNS lymphoma’ by Rubenstein et al.
|
Ghesquieres, H.
|
|
|
30 |
8 |
p. 1398-1399
|
artikel
|
| 32 |
Table of Contents
|
|
|
|
30 |
8 |
p. iv-vi
|
artikel
|
| 33 |
The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine
|
Loi, S.
|
|
|
30 |
8 |
p. 1183-1184
|
artikel
|
| 34 |
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
|
Souglakos, J.
|
|
|
30 |
8 |
p. 1304-1310
|
artikel
|
| 35 |
Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials
|
Borchmann, S.
|
|
|
30 |
8 |
p. 1329-1334
|
artikel
|
| 36 |
Timing of HPV16-E6 antibody seroconversion before OPSCC: findings from the HPVC3 consortium
|
Kreimer, A.R.
|
|
|
30 |
8 |
p. 1335-1343
|
artikel
|
| 37 |
Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma
|
Gambardella, V.
|
|
|
30 |
8 |
p. 1254-1264
|
artikel
|
Tijdschrift beschrijving